<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04457687</url>
  </required_header>
  <id_info>
    <org_study_id>E2023-A001-405</org_study_id>
    <nct_id>NCT04457687</nct_id>
  </id_info>
  <brief_title>Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies</brief_title>
  <official_title>Extended Access Program and Retrospective Chart Review for Lorcaserin in Dravet Syndrome and Other Refractory Epilepsies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to provide continued access of lorcaserin to
      participants with Dravet syndrome and other refractory epilepsies.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Epilepsies, Myoclonic</condition>
  <condition>Drug Resistant Epilepsy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin</intervention_name>
    <description>Lorcaserin 10 milligram (mg) tablets orally.</description>
    <other_name>E2023</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of Dravet syndrome (according to Recommendation from a North
             American Consensus Panel, 2017) or other refractory epilepsy (per the judgment of the
             treating physician)

          2. Male or female, age at least 2 years at the time of informed consent

          3. Currently treated with lorcaserin, that the treatment is for Dravet syndrome or other
             refractory epilepsies, and the treatment was initiated before 13 Feb 2020; or has
             completed Study E2023-A001-304

          4. Has a clinical benefit from lorcaserin in the opinion of the treating physician

        Exclusion Criteria:

        None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Eisai Medical Information</last_name>
    <phone>+1-888-274-2378</phone>
    <email>esi_medinfo@eisai.com</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extended Access Program</keyword>
  <keyword>Expanded Access Program</keyword>
  <keyword>Dravet Syndrome</keyword>
  <keyword>Refractory Epilepsies</keyword>
  <keyword>Lorcaserin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
    <mesh_term>Epilepsies, Myoclonic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

